Comparison of the Efficacy of Different Schemes for Using Recombinant Vector Vaccines against Ebola Fever, Based on Vaccinia Virus, MVA Strain

Comparison of the Efficacy of Different Schemes for Using Recombinant Vector Vaccines against Ebola Fever, Based on Vaccinia Virus, MVA Strain

The aim of this review was to investigate the use of the vaccines based on vaccinia virus, MVA stain, and adenovirus vectors for the prevention of Ebola virus disease. The recombinant MVA strains expressing antigen determinants of Filoviridae family representatives were assessed as possible candidat...

Full description

Bibliographic Details
Main Authors:	L. F. Stovba, O. V. Chukhralya, D. I. Pavel’ev, N. K. Chernikova, S. V. Borisevich
Format:	Article
Language:	Russian
Published:	Federal Government Health Institution, Russian Research Anti-Plague Institute “Microbe” 2024-01-01
Series:	Проблемы особо опасных инфекций
Subjects:	vaccinia virus mva strain ebola fever immunization priming booster dose immunodominant antigens multivalent vaccines
Online Access:	https://journal.microbe.ru/jour/article/view/1893

Similar Items

Using the vaccinia virus MVA strain for developing recombinant vector vaccines against current arboviral infections
by: L. F. Stovba, et al.
Published: (2021-11-01)

Safety and immunogenicity of IMVAMUNE®, a third-generation vaccine based on the modified vaccinia Ankara (MVA) strain
by: L. F. Stovba, et al.
Published: (2023-04-01)

Comparison of Recombinant MVA Selection Methods Based on F13L, D4R and K1L Genes
by: Irina V. Antoshkina, et al.
Published: (2022-03-01)

The Results of Clinical Trials of Recombinant Vaccine Virus, MVA Strain, Expressing Genes of Human Immunodeficiency Virus
by: L. F. Stovba, et al.
Published: (2021-10-01)

Analysis and Prospects of Using Recombinant Vaccinia Virus MVA Strain as a Vector in the Development of the Vaccines against Human and Simian Immunodeficiency Virus Diseases
by: L. F. Stovba, et al.
Published: (2019-07-01)

Expression of an Efficient Selection Marker Out of a Duplicated Site in the ITRs of a Modified Vaccinia Virus Ankara (MVA)
by: Sirine Abidi, et al.
Published: (2024-12-01)

A Genotype of Modified Vaccinia Ankara (MVA) that Facilitates Replication in Suspension Cultures in Chemically Defined Medium
by: Volker Sandig, et al.
Published: (2013-01-01)

Immunogenicity and efficacy of DNA/MVA HIV vaccines in rhesus macaque models
by: Lynette Siv Chea, et al.
Published: (2017-10-01)

The Effect of Previous Exposure to Malaria Infection and Clinical Malaria Episodes on the Immune Response to the Two-Dose Ad26.ZEBOV, MVA-BN-Filo Ebola Vaccine Regimen
by: Daniela Manno, et al.
Published: (2023-08-01)

Rapid Development of Modified Vaccinia Virus Ankara (MVA)-Based Vaccine Candidates Against Marburg Virus Suitable for Clinical Use in Humans
by: Alina Tscherne, et al.
Published: (2024-11-01)

Protective CD8+ T Cell Response Induced by Modified Vaccinia Virus Ankara Delivering Ebola Virus Nucleoprotein
by: Alexandra Kupke, et al.
Published: (2022-03-01)

Properties of Heterologous anti-Ebola Immunoglobulin after Long Storage
by: S. A. Melnikov, et al.
Published: (2020-03-01)

Ebola Hemorrhagic Fever Associated with Novel Virus Strain, Uganda, 2007–2008
by: Joseph F. Wamala, et al.
Published: (2010-07-01)

Long-Term Clinical Safety of the Ad26.ZEBOV and MVA-BN-Filo Ebola Vaccines: A Prospective, Multi-Country, Observational Study
by: Adeep Puri, et al.
Published: (2024-02-01)

Lot-to-lot consistency, immunogenicity, and safety of the Ad26.ZEBOV, MVA-BN-Filo Ebola virus vaccine regimen: A phase 3, randomized, double-blind, placebo-controlled trial
by: Neil Goldstein, et al.
Published: (2024-12-01)

A Pool of Eight Virally Vectored African Swine Fever Antigens Protect Pigs against Fatal Disease
by: Lynnette C. Goatley, et al.
Published: (2020-05-01)

EBOLA FEVER
by: V. A. Markin, et al.
Published: (2016-12-01)

Transgene expression knock-down in recombinant Modified Vaccinia virus Ankara vectors improves genetic stability and sustained transgene maintenance across multiple passages
by: Patrick Neckermann, et al.
Published: (2024-02-01)

MVA Vectored Vaccines Encoding Rift Valley Fever Virus Glycoproteins Protect Mice against Lethal Challenge in the Absence of Neutralizing Antibody Responses
by: Elena López-Gil, et al.
Published: (2020-02-01)

Immunogenicity and Safety of Modified Vaccinia Ankara (MVA) Vaccine—A Systematic Review and Meta-Analysis of Randomized Controlled Trials
by: Lior Nave, et al.
Published: (2023-08-01)

Elements in the Development of a Production Process for Modified Vaccinia Virus Ankara
by: Volker Sandig, et al.
Published: (2013-11-01)

Symptom-Based Ebola Risk Score for Ebola Virus Disease, Conakry, Guinea
by: Brecht Ingelbeen, et al.
Published: (2018-06-01)

Preclinical evaluation of a recombinant MVA expressing the hemagglutinin-neuraminidase envelope protein of parainfluenza virus 5 (Mammalian orthorubulavirus 5)
by: D.S.O. Daian e Silva, et al.
Published: (2023-06-01)

Ebola virus disease: past, present and future
by: Harish Rajak, et al.
Published: (2015-05-01)

Plasmablast, Memory B Cell, CD4+ T Cell, and Circulating Follicular Helper T Cell Responses to a Non-Replicating Modified Vaccinia Ankara Vaccine
by: Evan J. Anderson, et al.
Published: (2020-02-01)

A SOME ECOLOGICAL CHARACTERISTICS OF EBOLA VIRUS IN NATURAL FOCIES
by: T. E. Sizikova, et al.
Published: (2018-04-01)

Vaccinia virus induces endoplasmic reticulum stress and activates unfolded protein responses through the ATF6α transcription factor
by: Thiago Lima Leão, et al.
Published: (2023-07-01)

Requirements within the Ebola Viral Glycoprotein for Tetherin Antagonism
by: Nathan H. Vande Burgt, et al.
Published: (2015-10-01)

Effect of Recombinant Vesicular Stomatitis Virus–Zaire Ebola Virus Vaccination on Ebola Virus Disease Illness and Death, Democratic Republic of the Congo
by: Neil Rupani, et al.
Published: (2022-06-01)

Ebola Virus Infection
by: İlkay BOZKURT, et al.
Published: (2014-12-01)

Development of MVA-d34 Tetravalent Dengue Vaccine: Design and Immunogenicity
by: Ramil R. Mintaev, et al.
Published: (2023-04-01)

The Efficacy of Disinfection on Modified Vaccinia Ankara and African Swine Fever Virus in Various Forest Soil Types
by: Franziska Tanneberger, et al.
Published: (2021-10-01)

Vaccinia Virus in Household Environment during Bovine Vaccinia Outbreak, Brazil
by: Felipe L. Assis, et al.
Published: (2013-12-01)

Regional Spread of Ebola Virus, West Africa, 2014
by: Gabriel Rainisch, et al.
Published: (2015-03-01)

Ebola and Its Control in Liberia, 2014–2015
by: Tolbert G. Nyenswah, et al.
Published: (2016-02-01)

Immunogenic and Protective Features of the Recombinant Vaccinia Virus Strain Expressing Cassette of Genes of Marburg Virus Structural Proteins
by: A. V. Semenova, et al.
Published: (2022-01-01)

Immune response of a two-dose heterologous Ebola vaccine regimen: summary of three African clinical trials using a single validated Filovirus Animal Nonclinical Group enzyme-linked immunosorbent assay in a single accredited laboratoryResearch in context
by: Chelsea McLean, et al.
Published: (2023-05-01)

Smallpox Vaccine LC16m8: Production, Properties, and Prospects
by: L. F. Stovba, et al.
Published: (2024-10-01)

Liposomal and Suspension Forms of Immunoglobulins Against Ebola Fever as the New Medical Preparations
by: N. M. Zubavichene, et al.
Published: (2011-08-01)

A two-dose heterologous prime-boost vaccine regimen eliciting sustained immune responses to Ebola Zaire could support a preventive strategy for future outbreaks
by: Georgi Shukarev, et al.
Published: (2017-02-01)